Macro sensitivity: As a long-duration, growth-oriented technology fund, QTUM is highly sensitive to interest-rate and inflation trends, with the Federal Reserve's policy path a key swing factor for its future outlook. Thematic leverage: The ETF's future trajectory is tied to the commercialization of quantum computing, machine learning, and artificial intelligence infrastructure rather than to any single company's earnings.
U.S. cannabis rescheduling is the pivotal regulatory catalyst ahead, with Tilray positioning for a federally compliant medical market rather than adult-use retail. Beverage platform scale-up — led by the BrewDog acquisition and an exclusive U.S. Carlsberg licensing deal starting January 2027 — is central to the company's diversification strategy.
The $30 objective reflects the fund's disclosed 21.90% upside cap, which approximates the ceiling of what QJN is designed to return for the June 2026–May 2027 outcome period; it is not an analyst price target. Because QJN is a defined-outcome ETF, no credible aggregate of analyst price targets exists; the target is drawn from the issuer's published cap and buffer structure.
The $1.00 central target comes from public discussion of the asset-sale and CVR distribution value, not from an analyst consensus; there is no meaningful current sell-side coverage of ATER. With the latest verified price around $0.88, reaching $1.00 requires roughly a 14% advance, a modest move by the standards of this volatile micro-cap.
The central target used here is $26, the arithmetic mean of the two most recent verifiable sell-side analyst price targets — B of A Securities at $26 and Wedbush at $25 — though both are dated and coverage is thin. With Dream Finders Homes, Inc. (DFH) trading near $9.92, reaching $26 would require a roughly 162% advance — a very large move, not a modest one.
The central target of $66 is not an analyst consensus. As a leveraged inverse exchange-traded fund, SDS — the ProShares UltraShort S&P500 ETF — does not receive analyst price targets, so the figure is a technical, mean-reversion objective derived from public discussion and the fund's trailing trading range. The fund was recently trading near $59.50, meaning reaching $66 would require a gain of roughly 11%, a substantial move for a product that resets its exposure daily.
The central $10 target is the only publicly circulated 12-month price objective for BRAI , set by a single analyst (Maxim Group) in June 2026 — it is not a multi-analyst consensus. With shares recently trading near $1.48, reaching $10 would require a move of roughly 575%, a very large increase.
The $25.50 objective is a fallback price target drawn from public technical discussion, not an analyst consensus, because IBGA is an ETF and does not carry sell-side stock price targets. The latest verified market price is roughly $22.86, meaning reaching $25.50 would require a gain of about 11.5% — a substantial move for a bond fund.
The central stock price target of $12 reflects the arithmetic mean of seven individually attributed analyst price targets reviewed for BRCB , which span roughly $9 to $18. At a recent price near $9.58, reaching $12 would require a gain of about 25%, a substantial move rather than a modest one.
The central target of $43 is a fallback objective drawn from public discussion, anchored to the aggregate of analyst price targets on the roughly 850 stocks the fund holds — not a direct analyst target on CWI. At a recent price near $38.60, reaching $43 implies upside of roughly 11%, a modest move that would take the ETF above its 52-week high of $41.97.
The $16 central target is the arithmetic mean of two verified analyst price targets: BTIG's $20 (Buy) and Rothschild & Co Redburn's $12.88 (Neutral). The stock recently traded near $6.50, close to its 52-week low of $6.26, so reaching $16 would require roughly a 145% gain — a very large move.
NVOX is a 2X daily leveraged ETF tied to Novo Nordisk, not a common stock, so no individual analyst price targets exist for the fund itself. The $15 central target is a round-number technical recovery milestone drawn from public market discussion, not an analyst consensus or average price target.
The central target discussed here is $3.00 , roughly 33% above the fund's recent price near $2.25. This target is drawn from public quantitative-model discussion (a modeled three-month scenario range and naive forecast), not from a sell-side analyst consensus, because no analysts publish price targets for DJTU.
The central $1,150 stock price target is the arithmetic mean of roughly 15 current, attributable analyst price targets, rounded to a clean level. With ARGX trading near $925.70, reaching $1,150 requires an upside of about 24%, a substantial but not extreme move.
The $44 target discussed here is not an analyst consensus . It is a valuation-based objective drawn from public fair-value estimates, chiefly GuruFocus's GF Value (around $44) and independent discounted cash flow (DCF) models in the low-to-mid $40s. Published sell-side targets are materially lower: UBS analyst Peter Grom carries a Sell rating with a $31 price target (lowered from $32 in September 2026), and visible aggregators show an average analyst target near $31.
The central target used here is $48.50 , which would require a gain of roughly 16% from a recent price near $41.79. Because IVLU is an ETF, the target is drawn from public discussion and aggregated forecasts rather than a direct analyst consensus on the fund itself.
BBC is an ETF, not a stock, so the $55 objective is a fallback figure drawn from publicly discussed, holdings-derived implied targets rather than a direct analyst consensus. The fund traded near $43 recently, meaning a move to $55 would require roughly 28% upside — a substantial move.
The $112 central target is drawn from public discussion, not a published analyst consensus. ETFs do not receive sell-side price targets the way individual stocks do. TipRanks calculates a weighted average price target of about $112 for SPTM by aggregating 12-month analyst targets across its underlying holdings, implying roughly 22% upside from a price near $92.
Eversource Energy (ES) is a regulated electric, gas, and water utility serving New England, not an ETF; the central target used here is $80, roughly 12% above the latest price near $71.50. Because the overall average analyst price target of roughly $72 to $74 sits only marginally above the current price, the $80 central target is the average of the verified analyst targets above the current price, not the full Street mean.
The $18 central target reflects a technical milestone — a retest of the stock's 52-week high of $18.20 — rather than an analyst-derived consensus, because no sell-side firm currently publishes a price target for EFTY . The latest verified price is roughly $15.02, meaning a move to $18 would require an increase of about 20%, a substantial gain.